GH La Pitié Salpêtrière - CHU APHP
Welcome,         Profile    Billing    Logout  
 26 Trials 
30 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
DUBREUIL, Olivier
GASTFOX, NCT03006432: PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA

Completed
3
507
Europe, RoW
Oxaliplatin, 5Fluorouracil bolus, 5Fluorouracil continu, Docetaxel, Folinic Acid
Federation Francophone de Cancerologie Digestive, UNICANCER, GERCOR - Multidisciplinary Oncology Cooperative Group
OESOPHAGO-GASTRIC CARCINOMA
02/25
02/25
ADAGE, NCT02355379: Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over

Recruiting
3
774
Europe
LV5FU2 or capectitabine, FOLFOX4 or XELOX, Observation, LV5FU2 or capecitabine
Federation Francophone de Cancerologie Digestive
Colonic Adenocarcinoma
12/24
08/25
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
AQUATIC, NCT04217447: Assessment of Quitting Versus Using Aspirin Therapy in Patients Treated with Oral Anticoagulation for Atrial Fibrillation or Other Indication with Stabilized Coronary Artery Disease

Terminated
3
874
Europe
OAC + Aspirin 100mg od, OAC + placebo of Aspirin 100mg od
University Hospital, Brest, Bayer
Coronary Artery Disease
10/24
10/24
SCARCE, NCT03519295 / 2017-003185-27: A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma

Active, not recruiting
2
99
Europe
MPDL3280A, atezolizumab, mDCF, modified docetaxel, cisplatin, and fluorouracil
GERCOR - Multidisciplinary Oncology Cooperative Group, Roche Pharma AG
Anal Cancer
02/23
12/24
MAZEPPA, NCT04348045: Personalized Maintenance Therapy for m-PDAC Using Olaparib or Selumetinib + Durvalumab, Based on BRCAness and KRAS Status.

Active, not recruiting
2
307
Europe
Arm A - Olaparib, AZD-2281, ARM B - durvalumab plus selumetinib, MEDI-4736 plus AZD-6244, ARM C FOLFIRI, folinic acid, fluorouracil, and irinotecan
GERCOR - Multidisciplinary Oncology Cooperative Group, AstraZeneca
Metastatic Pancreatic Adenocarcinoma
07/23
12/24
POCHI, NCT04262687: Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate

Recruiting
2
55
Europe
Capecitabine, Oxaliplatin, Bevacizumab, Pembrolizumab
Federation Francophone de Cancerologie Digestive
Colorectal Cancer Metastatic, High Immune Infiltrate, Microsatellite Stable
09/24
09/24
FUDOSE, NCT06475352: Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme

Recruiting
2
400
Europe
FOLFOX regimen, CAPOX regimen
UNICANCER
Digestive Cancer, Colorectal Cancer
04/27
01/30
TRIFLUOX-DP, NCT06245356: Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

Recruiting
2
73
Europe
Lonsurf, Oxaliplatin, Panitumumab, Bevacizumab, Trastuzumab, Nivolumab
UNICANCER, Servier
Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency
10/26
10/28
PREMICES, NCT06646445: Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: Study.

Not yet recruiting
2
60
Europe
Pembrolizumab Injection [Keytruda], Keytruda, Watch-and-wait approach, Surgery, Adjuvant chemotherapy
GERCOR - Multidisciplinary Oncology Cooperative Group, Fondation ARCAD
Colon Cancer
12/27
12/29
LOGICAN, NCT05476796 / 2022-000273-81: Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

Recruiting
2
118
Europe
Trifluridine/Tipiracil, Lonsurf, Oxaliplatin, FOLFOX regimen, Nivolumab, OPDIVO
UNICANCER, Servier
Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
01/26
01/27
BETTER 2, NCT03351296 / 2017-000741-46: Two Chemotherapy Regimens Plus or Minus Bevacizumab

Active, not recruiting
2
140
Europe
LV5FU2, Streptozocin, Capecitabine, Temozolomide, Bevacizumab
Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France
Pancreatic Cancer
12/28
12/28
NEONEC, NCT04268121: Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas

Recruiting
2
78
Europe
Neoadjuvant treatment, cisplatin / cisplatinum, etoposide / vepesid, carbopatin / paraplatin, Adjuvant treatment
GERCOR - Multidisciplinary Oncology Cooperative Group, Fondation ARCAD
Neuroendocrine Carcinoma, Digestive Cancer
01/34
06/34
COBRAF, NCT05639413: A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

Recruiting
N/A
400
Europe
Collection of blood samples
UNICANCER, Pierre Fabre Medicament
Metastatic Colorectal Cancer, BRAF V600E Mutation Positive
07/27
07/28
Bachet, Jean-Baptiste
RePERSO, NCT04874207 / 2021-000252-18: Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients with Metastatic Colorectal Cancer Treated with REgorafenib

Active, not recruiting
4
110
Europe
Regorafenib
Rennes University Hospital, BAYER HEALTHCARE
Colorectal Cancer Metastatic
06/25
12/25
STRATEGIC-1, NCT01910610 / 2013-001928-19: Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer

Active, not recruiting
3
464
Europe, RoW
FOLFIRI-cetuximab, mFOLFOX6-bevacizumab, OPTIMOX-bevacizumab, irinotecan-based chemo + bevacizumab, Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab), XELOX + bevacizumab
GERCOR - Multidisciplinary Oncology Cooperative Group, Hoffmann-La Roche
Colorectal Cancer Metastatic
07/23
12/24
ADAGE, NCT02355379: Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over

Recruiting
3
774
Europe
LV5FU2 or capectitabine, FOLFOX4 or XELOX, Observation, LV5FU2 or capecitabine
Federation Francophone de Cancerologie Digestive
Colonic Adenocarcinoma
12/24
08/25
PHARBEVACOL, NCT06642844: Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment

Not yet recruiting
3
244
NA
Avastin, 25 Mg/mL Intravenous Solution, Experimental group, Control group
University Hospital, Tours, CHU DE BESANCON, Gustave Roussy, Cancer Campus, Grand Paris, CHU de Clermont-Ferrand, CHU de Reims, CHU de Brest, AP-HP, Hôpital Pitié- Salpétrière, CHU de Rouen, Poitiers University Hospital, Institut Paoli-Calmettes, Rennes University Hospital, University Hospital, Toulouse, AP-HP, Hôpital Saint-Louis, HCL Hôpital Edouard Hériot, Centre Hospitalier Universitaire Dijon, Nantes University Hospital, Centre Hospitalier Universitaire, Amiens, Hôpital Privé Jean Mermoz, AP-HP, Hôpital Henri Mondor, AP-HP, Hôpital Paul Brousse, CHG de St-Malo, Polyclinique de Blois, University Hospital, Caen, CHU de Nancy
Unresectable Metastatic Colorectal Cancer
10/28
10/29
GEMFOX, NCT04167007 / 2019-001364-30: FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX

Recruiting
3
400
Europe
Gemcitabine, FOLFOX
Assistance Publique - Hôpitaux de Paris
Pancreatic Adenocarcinoma
07/25
07/25
REPROGRAM-02, NCT05462613: Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer

Recruiting
2/3
446
Europe
quality of life questionnaires, Blood sample, Regorafenib, Metronomic chemotherapies, Aspirin, Bevacizumab, FOLFIRI or FOLFOX
Centre Hospitalier Universitaire de Besancon
Metastatic Colorectal Cancer
11/29
11/30
GABRINOX-ART, NCT04570943: Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

Recruiting
2
103
Europe
Gabrinox, MRI-GUIDED STEREOTACTIC RADIOTHERAPY
Institut du Cancer de Montpellier - Val d'Aurelle
Locally Advanced Pancreatic Adenocarcinoma
01/28
06/30
IMMUNOGAST, NCT04739202 / 2020-000297-17: Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma

Recruiting
2
60
Europe
Atezolizumab + Ipatasertib, Atezolizumab + Bevacizumab
Hospices Civils de Lyon, Roche, Inca
Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Adenocarcinoma, Advanced Gastric Carcinoma
10/23
10/23
OPTIPRIME, NCT03584711: FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation

Active, not recruiting
2
118
Europe, RoW
FOLFOX + panitumumab
Federation Francophone de Cancerologie Digestive, Amgen
Metastatic Colorectal Cancer
12/24
12/24
PANDAS, NCT02676349 / 2014-005681-29: Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (-PRODIGE 44)

Active, not recruiting
2
130
Europe
mFolfirinox, Chemoradiotherapy, surgery, Adjuvant chemotherapy
Institut de Cancérologie de Lorraine, Institut de Cancérologie de Lorraine Alexis Vautrin
Pancreatic Carcinoma
06/24
10/27
FUNGEMAX, NCT03693677 / 2017-004309-41: First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI

Active, not recruiting
2
288
Europe, RoW
Irinotecan Liposomal Injection, Nal-IRI, 5-FU/LV, Nab-Paclitaxel, Gemcitabine
Federation Francophone de Cancerologie Digestive
Metastatic Pancreatic Cancer
07/25
12/25
SOREGATT, NCT04450836 / 2019-004196-39: Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer

Terminated
2
234
Europe
Regorafenib then Trifluridine/Tipiracil, STIVARGA, LONSURF, Trifluridine/Tipiracil then Regorafenib
UNICANCER, Bayer HealthCare Pharmaceuticals Inc.
Metastatic Colorectal Cancer
03/24
12/24
AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active, not recruiting
2
154
Europe, Canada, Japan, US, RoW
Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A
GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd
Neoplasms, Rectal
11/26
10/29
LAP-NET1, NCT05546853: Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma

Active, not recruiting
1
43
Europe
NP137, Oxaliplatin, Irinotecan, Calcium levofolinate, 5 FU
University Hospital, Grenoble, NETRIS Pharma
Pancreatic Ductal Adenocarcinoma
12/24
06/25
COBRAF, NCT05639413: A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

Recruiting
N/A
400
Europe
Collection of blood samples
UNICANCER, Pierre Fabre Medicament
Metastatic Colorectal Cancer, BRAF V600E Mutation Positive
07/27
07/28
DOAT, Solène
ADAGE, NCT02355379: Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over

Recruiting
3
774
Europe
LV5FU2 or capectitabine, FOLFOX4 or XELOX, Observation, LV5FU2 or capecitabine
Federation Francophone de Cancerologie Digestive
Colonic Adenocarcinoma
12/24
08/25
MORYOUSSEF, Frederick
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
DUBREUIL, Olivier
GASTFOX, NCT03006432: PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA

Completed
3
507
Europe, RoW
Oxaliplatin, 5Fluorouracil bolus, 5Fluorouracil continu, Docetaxel, Folinic Acid
Federation Francophone de Cancerologie Digestive, UNICANCER, GERCOR - Multidisciplinary Oncology Cooperative Group
OESOPHAGO-GASTRIC CARCINOMA
02/25
02/25
ADAGE, NCT02355379: Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over

Recruiting
3
774
Europe
LV5FU2 or capectitabine, FOLFOX4 or XELOX, Observation, LV5FU2 or capecitabine
Federation Francophone de Cancerologie Digestive
Colonic Adenocarcinoma
12/24
08/25
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
AQUATIC, NCT04217447: Assessment of Quitting Versus Using Aspirin Therapy in Patients Treated with Oral Anticoagulation for Atrial Fibrillation or Other Indication with Stabilized Coronary Artery Disease

Terminated
3
874
Europe
OAC + Aspirin 100mg od, OAC + placebo of Aspirin 100mg od
University Hospital, Brest, Bayer
Coronary Artery Disease
10/24
10/24
SCARCE, NCT03519295 / 2017-003185-27: A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma

Active, not recruiting
2
99
Europe
MPDL3280A, atezolizumab, mDCF, modified docetaxel, cisplatin, and fluorouracil
GERCOR - Multidisciplinary Oncology Cooperative Group, Roche Pharma AG
Anal Cancer
02/23
12/24
MAZEPPA, NCT04348045: Personalized Maintenance Therapy for m-PDAC Using Olaparib or Selumetinib + Durvalumab, Based on BRCAness and KRAS Status.

Active, not recruiting
2
307
Europe
Arm A - Olaparib, AZD-2281, ARM B - durvalumab plus selumetinib, MEDI-4736 plus AZD-6244, ARM C FOLFIRI, folinic acid, fluorouracil, and irinotecan
GERCOR - Multidisciplinary Oncology Cooperative Group, AstraZeneca
Metastatic Pancreatic Adenocarcinoma
07/23
12/24
POCHI, NCT04262687: Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate

Recruiting
2
55
Europe
Capecitabine, Oxaliplatin, Bevacizumab, Pembrolizumab
Federation Francophone de Cancerologie Digestive
Colorectal Cancer Metastatic, High Immune Infiltrate, Microsatellite Stable
09/24
09/24
FUDOSE, NCT06475352: Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme

Recruiting
2
400
Europe
FOLFOX regimen, CAPOX regimen
UNICANCER
Digestive Cancer, Colorectal Cancer
04/27
01/30
TRIFLUOX-DP, NCT06245356: Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

Recruiting
2
73
Europe
Lonsurf, Oxaliplatin, Panitumumab, Bevacizumab, Trastuzumab, Nivolumab
UNICANCER, Servier
Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency
10/26
10/28
PREMICES, NCT06646445: Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: Study.

Not yet recruiting
2
60
Europe
Pembrolizumab Injection [Keytruda], Keytruda, Watch-and-wait approach, Surgery, Adjuvant chemotherapy
GERCOR - Multidisciplinary Oncology Cooperative Group, Fondation ARCAD
Colon Cancer
12/27
12/29
LOGICAN, NCT05476796 / 2022-000273-81: Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

Recruiting
2
118
Europe
Trifluridine/Tipiracil, Lonsurf, Oxaliplatin, FOLFOX regimen, Nivolumab, OPDIVO
UNICANCER, Servier
Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
01/26
01/27
BETTER 2, NCT03351296 / 2017-000741-46: Two Chemotherapy Regimens Plus or Minus Bevacizumab

Active, not recruiting
2
140
Europe
LV5FU2, Streptozocin, Capecitabine, Temozolomide, Bevacizumab
Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France
Pancreatic Cancer
12/28
12/28
NEONEC, NCT04268121: Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas

Recruiting
2
78
Europe
Neoadjuvant treatment, cisplatin / cisplatinum, etoposide / vepesid, carbopatin / paraplatin, Adjuvant treatment
GERCOR - Multidisciplinary Oncology Cooperative Group, Fondation ARCAD
Neuroendocrine Carcinoma, Digestive Cancer
01/34
06/34
COBRAF, NCT05639413: A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

Recruiting
N/A
400
Europe
Collection of blood samples
UNICANCER, Pierre Fabre Medicament
Metastatic Colorectal Cancer, BRAF V600E Mutation Positive
07/27
07/28
Bachet, Jean-Baptiste
RePERSO, NCT04874207 / 2021-000252-18: Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients with Metastatic Colorectal Cancer Treated with REgorafenib

Active, not recruiting
4
110
Europe
Regorafenib
Rennes University Hospital, BAYER HEALTHCARE
Colorectal Cancer Metastatic
06/25
12/25
STRATEGIC-1, NCT01910610 / 2013-001928-19: Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer

Active, not recruiting
3
464
Europe, RoW
FOLFIRI-cetuximab, mFOLFOX6-bevacizumab, OPTIMOX-bevacizumab, irinotecan-based chemo + bevacizumab, Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab), XELOX + bevacizumab
GERCOR - Multidisciplinary Oncology Cooperative Group, Hoffmann-La Roche
Colorectal Cancer Metastatic
07/23
12/24
ADAGE, NCT02355379: Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over

Recruiting
3
774
Europe
LV5FU2 or capectitabine, FOLFOX4 or XELOX, Observation, LV5FU2 or capecitabine
Federation Francophone de Cancerologie Digestive
Colonic Adenocarcinoma
12/24
08/25
PHARBEVACOL, NCT06642844: Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment

Not yet recruiting
3
244
NA
Avastin, 25 Mg/mL Intravenous Solution, Experimental group, Control group
University Hospital, Tours, CHU DE BESANCON, Gustave Roussy, Cancer Campus, Grand Paris, CHU de Clermont-Ferrand, CHU de Reims, CHU de Brest, AP-HP, Hôpital Pitié- Salpétrière, CHU de Rouen, Poitiers University Hospital, Institut Paoli-Calmettes, Rennes University Hospital, University Hospital, Toulouse, AP-HP, Hôpital Saint-Louis, HCL Hôpital Edouard Hériot, Centre Hospitalier Universitaire Dijon, Nantes University Hospital, Centre Hospitalier Universitaire, Amiens, Hôpital Privé Jean Mermoz, AP-HP, Hôpital Henri Mondor, AP-HP, Hôpital Paul Brousse, CHG de St-Malo, Polyclinique de Blois, University Hospital, Caen, CHU de Nancy
Unresectable Metastatic Colorectal Cancer
10/28
10/29
GEMFOX, NCT04167007 / 2019-001364-30: FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX

Recruiting
3
400
Europe
Gemcitabine, FOLFOX
Assistance Publique - Hôpitaux de Paris
Pancreatic Adenocarcinoma
07/25
07/25
REPROGRAM-02, NCT05462613: Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer

Recruiting
2/3
446
Europe
quality of life questionnaires, Blood sample, Regorafenib, Metronomic chemotherapies, Aspirin, Bevacizumab, FOLFIRI or FOLFOX
Centre Hospitalier Universitaire de Besancon
Metastatic Colorectal Cancer
11/29
11/30
GABRINOX-ART, NCT04570943: Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

Recruiting
2
103
Europe
Gabrinox, MRI-GUIDED STEREOTACTIC RADIOTHERAPY
Institut du Cancer de Montpellier - Val d'Aurelle
Locally Advanced Pancreatic Adenocarcinoma
01/28
06/30
IMMUNOGAST, NCT04739202 / 2020-000297-17: Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma

Recruiting
2
60
Europe
Atezolizumab + Ipatasertib, Atezolizumab + Bevacizumab
Hospices Civils de Lyon, Roche, Inca
Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Adenocarcinoma, Advanced Gastric Carcinoma
10/23
10/23
OPTIPRIME, NCT03584711: FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation

Active, not recruiting
2
118
Europe, RoW
FOLFOX + panitumumab
Federation Francophone de Cancerologie Digestive, Amgen
Metastatic Colorectal Cancer
12/24
12/24
PANDAS, NCT02676349 / 2014-005681-29: Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (-PRODIGE 44)

Active, not recruiting
2
130
Europe
mFolfirinox, Chemoradiotherapy, surgery, Adjuvant chemotherapy
Institut de Cancérologie de Lorraine, Institut de Cancérologie de Lorraine Alexis Vautrin
Pancreatic Carcinoma
06/24
10/27
FUNGEMAX, NCT03693677 / 2017-004309-41: First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI

Active, not recruiting
2
288
Europe, RoW
Irinotecan Liposomal Injection, Nal-IRI, 5-FU/LV, Nab-Paclitaxel, Gemcitabine
Federation Francophone de Cancerologie Digestive
Metastatic Pancreatic Cancer
07/25
12/25
SOREGATT, NCT04450836 / 2019-004196-39: Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer

Terminated
2
234
Europe
Regorafenib then Trifluridine/Tipiracil, STIVARGA, LONSURF, Trifluridine/Tipiracil then Regorafenib
UNICANCER, Bayer HealthCare Pharmaceuticals Inc.
Metastatic Colorectal Cancer
03/24
12/24
AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active, not recruiting
2
154
Europe, Canada, Japan, US, RoW
Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A
GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd
Neoplasms, Rectal
11/26
10/29
LAP-NET1, NCT05546853: Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma

Active, not recruiting
1
43
Europe
NP137, Oxaliplatin, Irinotecan, Calcium levofolinate, 5 FU
University Hospital, Grenoble, NETRIS Pharma
Pancreatic Ductal Adenocarcinoma
12/24
06/25
COBRAF, NCT05639413: A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

Recruiting
N/A
400
Europe
Collection of blood samples
UNICANCER, Pierre Fabre Medicament
Metastatic Colorectal Cancer, BRAF V600E Mutation Positive
07/27
07/28
DOAT, Solène
ADAGE, NCT02355379: Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over

Recruiting
3
774
Europe
LV5FU2 or capectitabine, FOLFOX4 or XELOX, Observation, LV5FU2 or capecitabine
Federation Francophone de Cancerologie Digestive
Colonic Adenocarcinoma
12/24
08/25
MORYOUSSEF, Frederick
No trials found

Download Options